

Both all speakers are requested to make the poster.

Please kindly check the detail on page.

Registration ID	Date of Presentation	Session	Presentation Order	Title of Abstract
id001	12/8 17:05-18:35	Moderated Poster 1 (ex-Oral Presentation 1)	1	A mitochondria-targeted drug induces apoptosis in prostate cancer xenografts
id002	12/9 11:00-12:00	Moderated Poster 2 (ex-Oral Presentation 2)	8	Biology and usefulness of [-2]proPSA as a prognostic marker in CRPC patients
id003	12/8 17:05-18:35	Moderated Poster 1 (ex-Oral Presentation 1)	3	Combination therapy with novel androgen receptor antagonists and statin for castration - resistant prostate cancer
id004	12/8 17:05-18:35	Moderated Poster 1 (ex-Oral Presentation 1)	13	Novel Nomogram Predicting Biochemical Recurrence-Free Survival After Radical Prostatectomy
id005	12/8 17:05-18:35	Moderated Poster 1 (ex-Oral Presentation 1)	5	GDF15 propeptide is a novel and useful biomarker for bone metastases in prostate cancer
id006	12/8 17:05-18:35	Moderated Poster 1 (ex-Oral Presentation 1)	4	Lipopolysaccharide from dysbiotic gut microbiome promotes prostate cancer growth through histamine H1 receptor signaling
id007	12/8 17:05-18:35	Moderated Poster 1 (ex-Oral Presentation 1)	7	Is 12 Systemic Cores in Transperineal Biopsy Sufficient for Detecting Clinically Significant Prostate Cancer?
id008	12/9 11:00-12:00	Moderated Poster 2 (ex-Oral Presentation 2)	4	Switching to darolutamide for M0CRPC resistant to enzalutamide or apalutamide
id009	12/9 11:00-12:00	Moderated Poster 2 (ex-Oral Presentation 2)	5	Efficacy and Safety of Enzalutamide and Apalutamide in the Treatment of Patients with nmCRPC: A retrospective analysis
id011	12/9 11:00-12:00	Moderated Poster 2 (ex-Oral Presentation 2)	7	Cisplatin and Etoposide for treatment-related Neuroendocrine Prostate Cancer: favorable early Response with short Duration
id012	12/8 17:05-18:35	Moderated Poster 1 (ex-Oral Presentation 1)	9	Clinicopathological analysis of prostate cancer with lymph node metastasis in the prostatic anterior fat pad
id013	12/8 17:05-18:35	Moderated Poster 1 (ex-Oral Presentation 1)	12	Comparison of longitudinal health - related QOL outcomes between anterior and posterior approaches to robot - assisted radical prostatectomy
id014	12/8 17:05-18:35	Moderated Poster 1 (ex-Oral Presentation 1)	11	Early outcomes of Single port robotic radical prostatectomy : 1 year followed up
id015	12/8 17:05-18:35	Moderated Poster 1 (ex-Oral Presentation 1)	14	Carbon-ion radiotherapy for high-risk prostate cancer in Gunma University Heavy Ion Medical Center
id016	12/9 11:00-12:00	Moderated Poster 2 (ex-Oral Presentation 2)	3	PSA doubling time predicts the efficiency of site-directed therapy for non-metastatic or oligometastatic CRPC
id017	12/8 17:05-18:35	Moderated Poster 1 (ex-Oral Presentation 1)	15	Salvage low-dose rate brachytherapy for local recurrence of prostate cancer after radical radiotherapy
id018	12/9 11:00-12:00	Moderated Poster 2 (ex-Oral Presentation 2)	9	The Effects of Personal and Family Cancer History on the Diagnosis of Prostate Cancer in a Multi-Institutional Prostate Biopsy Registry
id019	Display only	Unmoderated Poster		The Association of Anatomical Structural with Voiding Functions in Men with Benign Prostatic Hyperplasia/ Lower Urinary Tract Symptoms
id020	Display only	Unmoderated Poster		Role of the Elastography Strain Ratio using Transrectal Ultrasonography in the Diagnosis of Clinically Significant Prostate Cancer
id021	12/9 11:00-12:00	Moderated Poster 2 (ex-Oral Presentation 2)	2	The Association between Human Gut Microbiota and Benign Prostatic Hyperplasia
id022	12/8 17:05-18:35	Moderated Poster 1 (ex-Oral Presentation 1)	8	The Impact of mpMRI on Treatment Strategy for Incidental Prostate Cancer after HoLEP
id023	Display only	Unmoderated Poster		Clinical Utility of Confirmatory Transperineal Template-Guided Saturation Prostate Biopsy after TRUS-Bx on Treatment Outcome of Focal HIFU
id024	Display only	Unmoderated Poster		The characteristics of patients with prostate specific antigen persistence after Robot Assisted Radical Prostatectomy
id025	12/9 11:00-12:00	Moderated Poster 2 (ex-Oral Presentation 2)	1	Changes of resistance indices after medication in benign prostatic hyperplasia: a prospective study
id026	12/8 17:05-18:35	Moderated Poster 1 (ex-Oral Presentation 1)	6	Circulating tumor cell based transcriptomic differences between localized and metastatic prostate cancer
id027	12/8 17:05-18:35	Moderated Poster 1 (ex-Oral Presentation 1)	10	Robotic-Assisted Simple Prostatectomy using the da Vinci SP system, pilot study
id028	Display only	Unmoderated Poster		Periprocedural adverse events and distribution of the SpaceOAR hydrogel for radiotherapy for prostate cancer
id029	Display only	Unmoderated Poster		How to deal with PI-RADS category3 cases?
id030	Display only	Unmoderated Poster		MRI-TRUS Fusion Biopsies: 30 cases of primary experience
id031	12/9 11:00-12:00	Moderated Poster 2 (ex-Oral Presentation 2)	6	How I recruit the suitable nmCRPC patients for taking insurance-reimbursed Darolutamide in Taiwan
id032	Display only	Unmoderated Poster		Clinical Analysis of Intensity modulated radiation therapy(IMRT) for localized prostate cancer at Showa University
id033	12/8 17:05-18:35	Moderated Poster 1 (ex-Oral Presentation 1)	2	Hyperforin Induces Extrinsic/Intrinsic Apoptosis Signaling and Inhibits NF- κ B for Metastasis Suppression in Prostate Cancer Cells
id034	12/9 11:00-12:00	Moderated Poster 2 (ex-Oral Presentation 2)	10	Risk of urinary tract infection in prostate cancer patients who treated with radiation therapy or radical prostatectomy
id035	Display only	Unmoderated Poster		Immune checkpoint molecules-targeting recombinant dendritic cells for therapeutic effect on prostate cancer
id036	Display only	Unmoderated Poster		Robot-assisted laparoscopic radical prostatectomy (RARP) induction results and comparison with open radical prostatectomy(ORR)